Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | TNKS | O95271 | 7/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648958 | 0.89 | PTPN1 (0.59) | PTPN1PTPN2 | |
| SCHEMBL646151 | 0.87 | PTPN1 (0.60) | PTPN1PTPN2 | |
| SCHEMBL647149 | 0.87 | PTPN1 (0.57) | PTPN1P2RX7PTPN2 | |
| SCHEMBL647910 | 0.82 | PTPN1 (0.58) | PTPN1PTPN2 | |
| SCHEMBL646524 | 0.81 | PTPN1 (0.49) | PTPN1PTPN2 | |
| SCHEMBL649046 | 0.80 | PTPN1 (0.43) | PTPN1P2RX7PTPN2 | |
| SCHEMBL2933467 | 0.80 | PTPN1 (0.58) | PTPN1PTPN2 | |
| SCHEMBL3226681 | 0.79 | PTPN1 (0.63) | PTPN1PTPN2 | |
| SCHEMBL647598 | 0.78 | PTPN1 (0.60) | PTPN1PTPN2 | |
| SCHEMBL649557 | 0.77 | PTPN1 (0.64) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | PTPN1 17/4885P2RX7 2025/4885TNKS 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.